129 related articles for article (PubMed ID: 6204932)
1. An experimental immunocytoma model in /LOU/M/Ws1 X CFY/F1 rats: neoplastic cells as targets of the host's immune apparatus.
Puskás E; Uher F; Gergely J; Bazin H
Immunology; 1984 Jul; 52(3):547-54. PubMed ID: 6204932
[No Abstract] [Full Text] [Related]
2. An IgM-producing immunocytoma induces large numbers of splenic T lymphocytes with Fc mu receptors.
Uher F; Puskás E; Gergely J; Bazin H
Immunology; 1987 Jul; 61(3):327-32. PubMed ID: 3497090
[TBL] [Abstract][Full Text] [Related]
3. [Circulating IgG-containing immune complexes in malignant growth].
Kostrzhevskaia EG
Eksp Onkol; 1986; 8(3):10-7. PubMed ID: 2424714
[TBL] [Abstract][Full Text] [Related]
4. The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma.
Hatzubai A; Maloney DG; Levy R
J Immunol; 1981 Jun; 126(6):2397-402. PubMed ID: 6785351
[TBL] [Abstract][Full Text] [Related]
5. The alloantibody response in the allogeneically pregnant rat. VI. Detection in maternal serum of specific antigen-antibody complexes.
Amsden AF; Smith RN; Chirakalwasan N
J Immunol; 1988 Oct; 141(7):2295-302. PubMed ID: 2459205
[TBL] [Abstract][Full Text] [Related]
6. A transplantable immunocytoma of the rat as a model for the study of immunoglobulin secretion.
Deckers C; Deckers-Passau L; Dubucq-mace F
Lab Anim Sci; 1977 Oct; 27(5 Pt 2):733-7. PubMed ID: 338977
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing localization of labeled antibodies in tumors.
Bale WF; Contreras MA; Grady ED
Cancer Res; 1980 Aug; 40(8 Pt 2):2965-72. PubMed ID: 7397692
[TBL] [Abstract][Full Text] [Related]
8. Drug-mediated changes of tumour cell immunogenicity and antigenicity.
Puccetti P; Romani L; Taramelli D; Bonmassar E; Fioretti MC
Int J Tissue React; 1982; 4(3):189-99. PubMed ID: 6183194
[No Abstract] [Full Text] [Related]
9. Genetic control of the resistance to spontaneous immunocytoma (plasmacytoma-IR tumour) development in LOU/C rats.
Bazin H; Kints JP; Rousseaux J
Anticancer Res; 1986; 6(1):45-8. PubMed ID: 3954329
[TBL] [Abstract][Full Text] [Related]
10. Recognition of allo-MHC antigens in the self-MHC context.
Wigzell H; Binz H
Transplant Proc; 1982 Sep; 14(3):541-2. PubMed ID: 6817480
[No Abstract] [Full Text] [Related]
11. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
12. [Antigen-dependent nonspecific immunoglobulins. Their nature and possible mechanisms of formation].
Sidorova EV
Vestn Akad Med Nauk SSSR; 1988; (5):20-30. PubMed ID: 2459861
[No Abstract] [Full Text] [Related]
13. [Immunological properties of tumor cells that determine the degree of their malignancy].
Lavrovskiĭ VA; Viksler VKh
Usp Sovrem Biol; 1981; 91(2):228-40. PubMed ID: 7018110
[No Abstract] [Full Text] [Related]
14. [The LOUVAIN rat and its importance in cancerology].
Bazin H; Beckers A; Platteau B; Kints JP
Acta Zool Pathol Antverp; 1979 Jun; (72):35-44. PubMed ID: 495386
[TBL] [Abstract][Full Text] [Related]
15. B-cell malignancy and monoclonal gammopathy, and idiotype of cell surface and serum immunoglobulin.
Sugai S; Takiguchi T; Hirose Y; Konaka Y; Shimizu S; Konda S
Jpn J Clin Oncol; 1983 Sep; 13(3):533-42. PubMed ID: 6417376
[TBL] [Abstract][Full Text] [Related]
16. Specific blocking factors--are they important?
Hellström KE; Hellström I; Nepom JT
Biochim Biophys Acta; 1977 Dec; 473(2):121-48. PubMed ID: 73383
[No Abstract] [Full Text] [Related]
17. T cell tumors, clones, and hybrids.
Ruddle NH
Prog Allergy; 1981; 29():222-68. PubMed ID: 7036181
[No Abstract] [Full Text] [Related]
18. The control of the immune response.
Asherson GL
Ann Allergy; 1984 Dec; 53(6 Pt 2):557-62. PubMed ID: 6209999
[No Abstract] [Full Text] [Related]
19. A framework hypothesis on the development of an immune system selected by histocompatibility antigens.
Caulfield MJ
Scand J Immunol; 1986 Nov; 24(5):491-502. PubMed ID: 2431459
[No Abstract] [Full Text] [Related]
20. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
